touchPODCAST

Is HER2 targeting on the horizon for urothelial carcinoma?

touchFOCUS for touchONCOLOGY

A genitourinary medical oncologist considers the potential for targeting HER2 in the treatment of urothelial carcinoma, including the rationale for HER2 as a target, approaches to HER2 testing, the latest data on emerging HER2-targeted therapies and the potential implications for future clinical practice. 

The expert:

• Dr Vadim Koshkin - University of California San Francisco, CA, USA
  

This touchPODCAST is for HCPs only. 

This activity is funded by an independent medical education grant from Seagen Inc. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: touchoncology.com

Addressing challenges in diagnosis and treatment of IgG4-related gastrointestinal disease

touchIN CONVERSATION for touchIMMUNOLOGY

Listen to Dr Shounak Majumder (Mayo Clinic, Rochester, MN, USA) in conversation with Professor Matthias Löhr (Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden) on how to optimize the diagnosis and management of patients with IgG4-related gastrointestinal (GI) disease. 

They respond to questions from the gastroenterology, hepatology and rheumatology clinical communities on:

• Challenges of diagnosing IgG4-related GI disease
• Differentiating type 1 autoimmune pancreatitis from type 2
• Therapeutic strategies for IgG4-related GI disease

This touchPODCAST is for HCPs only. 

This activity is funded by an independent medical education grant from Horizon Therapeutics. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: touchimmunology.com

Haemato-oncology experts discuss current considerations and future strategies for CAR T-cell therapies in patients with R/R MCL

touchIN CONVERSATION for touchONCOLOGY

Listen to a conversation between haemato-oncologists Dr Matthew Matasar and Dr Amitkumar Mehta, as they respond to questions submitted by the HCP audience and provide their expert insights on the current considerations and future strategies when managing the practicalities of CAR T-cell therapies in patients with relapsed or refractory mantle cell lymphoma.

This touchPODCAST is for HCPs only. This activity is funded by an independent medical education grant from Bristol Myers Squibb. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: touchoncology.com

Haemato-oncology experts discuss current considerations and future strategies for CAR T-cell therapies in patients with R/R MCL

touchIN CONVERSATION for touchHAEMATOLOGY

Listen to a conversation between haemato-oncologists Dr Matthew Matasar and Dr Amitkumar Mehta, as they respond to questions submitted by the HCP audience and provide their expert insights on the current considerations and future strategies when managing the practicalities of CAR T-cell therapies in patients with relapsed or refractory mantle cell lymphoma.

This touchPODCAST is for HCPs only. This activity is funded by an independent medical education grant from Bristol Myers Squibb. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: touchhaematology.com

Overcoming challenges in advanced or metastatic squamous cell lung cancer: Focus on immunotherapy

touchFOCUS for touchONCOLOGY

Listen to Dr Balazs Halmos answer a series of questions focused on the distinctive clinical features of squamous cell lung cancer, the challenges they pose to developing a treatment plan, and the role immunotherapy plays in overcoming them. 

The expert:

• Dr Balazs Halmos - Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, NY, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Regeneron. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: touchoncology.com/

Overcoming challenges in advanced or metastatic squamous cell lung cancer: Focus on immunotherapy

touchFOCUS for touchRESPIRATORY

Listen to Dr Balazs Halmos answer a series of questions focused on the distinctive clinical features of squamous cell lung cancer, the challenges they pose to developing a treatment plan, and the role immunotherapy plays in overcoming them. 

The expert:

• Dr Balazs Halmos - Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, NY, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Regeneron. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: touchrespiratoryime.org/

Haemato-oncology experts discuss managing the practicalities of CAR T-cell therapy in relapsed or refractory follicular lymphoma

touchIN CONVERSATION for touchONCOLOGY

Listen to Dr Nilanjan Ghosh in conversation with Dr Peter Riedell. They respond to questions submitted by the HCP audience and provide their expert insights regarding new horizons in relapsed or refractory follicular lymphoma, with a focus on risk stratification and managing the practicalities of CAR T-cell therapy.

This touchPODCAST is for HCPs only. This activity is funded by an unrestricted independent medical educational grant from Bristol Myers Squibb and is jointly provided by USF Health and touchIME.

For further information visit our website: touchoncology.com/ 

Haemato-oncology experts discuss managing the practicalities of CAR T-cell therapy in relapsed or refractory follicular lymphoma

touchIN CONVERSATION for touchHAEMATOLOGY

Listen to Dr Nilanjan Ghosh in conversation with Dr Peter Riedell. They respond to questions submitted by the HCP audience and provide their expert insights regarding new horizons in relapsed or refractory follicular lymphoma, with a focus on risk stratification and managing the practicalities of CAR T-cell therapy.

This touchPODCAST is for HCPs only. This activity is funded by an independent medical educational grant from Bristol Myers Squibb and is jointly provided by USF Health and touchIME. 

For further information visit our website: https://touchhaematologyime.org/

Advances in IOL technology and power calculations: Updates and innovations

touchFOCUS for touchOPHTHALMOLOGY

Listen to Dr John Hovanesian answer a series of questions focused on how to effectively manage patients prior to cataract surgery and ensure the most appropriate intraocular lens (IOL) formula is used, including his views on recent advances in IOL technology. 

The expert:

• Dr John Hovanesian, University of California, Los Angeles, Jules Stein Eye Institute, CA, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Alcon Vision, LLC,. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: touchophthalmologyime.org/advances-in-iol-technology-and-power-calculations-updates-and-innovations/

Guideline-based treatment of recurrent/metastatic cervical cancer

touchEXPERT OPINIONS for touchONCOLOGY

 Two oncologists summarize the latest US and European guidelines for the treatment of recurrent/metastatic cervical cancer and a nurse practitioner considers key safety considerations for immunotherapy and targeted treatments.

The experts

• Dr David O’Malley - James Comprehensive Cancer Center, Columbus, OH, USA
• Dr Domenica Lorusso - La Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy,
• Courtney Arn – The Ohio State University, Columbus, OH, USA

This touchPODCAST is for HCPs only.

 This activity is funded by an independent medical educational grant from Merck and Co., Inc and Seagen Inc. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: touchoncologyime.org/guideline-management-recurrent-metastatic-cervical-cancer